Central Avalonian Psychoactive Substances Act

{Infobox organization }
 * name             = Central Avalonian Psychoactive Substances Act
 * image            =
 * image_size       =
 * map              =
 * map_size         =
 * map_caption      =
 * abbreviation     = CAPSA
 * founded          = 20 April 2017
 * founding_location =
 * dissolved        =
 * type             = Intergovernmental Organisation, Economic and Political Treaty
 * headquarters     = Masazi, Baileneu Ma
 * num_members_year =
 * membership       = {{plainlist|
 * leader_title     =
 * leader_name      =
 * leader_title2    =
 * leader_name2     =
 * affiliations     =
 * leader_name      =
 * leader_title2    =
 * leader_name2     =
 * affiliations     =

The Central Avalonian Psychoactive Substances Act is a multinational treaty dedicated to scheduling psychoactive substances based on potential for abuse, physical harm to user and psychological harm to user. The CAPSA covers stimulants, hallucinogens, depressants and opiates, both natural and synthetic, in order to create a conclusive and science based drug classification system in order to encourage more nations to re-evaluate their positions on drug legality. The main aims of CAPSA is for the legalisation of cannabis and the legalisation/decriminalisation of psychedelic substances in Avalonia, although the only current members are Baileneu Ma, Zahava, Tavaluda, Tilenno, Fordorsia, Arbenz and Iere. The treaty also covers isomers, esters, ethers, salts and other analogues of listed substances, as well as covering many of the precursors to the drugs, however plants used in the extraction of substances are not scheduled.

Avalonian Advisory Board on Psychoactive Substances (AABPS)
The Avalonian Advisory Board on Psychoactive Substances is a council of advisors from various professions (primarily well-established doctors, psychologists and neurologists) that counsel drug laws in member nations, as well as working on harm reduction education for schools and rehabilitation centers. In recent years, AABPS has worked together with the NHS in developing fourth generation tryptamine based medication and in recent studies for the use of MDMA and other psychedelics in therapy use. AABPS also orchestrated a trade deal between member nations, giving preferential purchasing rights and reduced tariffs in the trade of pyschoactive substances between nations that have signed the act, leading to small economic booms in Iere and Baileneu Ma. The AABPS has also pushed for psychedelic and cannabis legalisation in other nations, with limited success, although it did manage to push cannabis decriminalisation in Liao and cannabis legalisation in Terres Riveraines.

Licensing and Regulations
All drug manufactures must test for impurities for every batch produced, where only trace amounts of other chemicals are allowed if they are deemed harmless. All manufacturers must also be licensed by a national committee in order to produce synthetic substances in order to ensure that all drugs produced are safe and well produced. Retailers must state the typical duration of the substance, how it reacts with other substances and how it can impact existing health conditions/create new ones. If a death occurs due to impurities in a substance sold, the retailer and manufacturer can be held liable to a revocation of license, fines up to $1 million and/or imprisonment for murder or manslaughter.

Scheduling
Member nations of the treaty are still able to have their own autonomy when it comes to drug scheduling, where certain illicit substances can be made available for both recreational and medical use. This is used as a guideline for nations based on the risk assessment and evaluation of experts.